Corcept Therapeutics Submits New Drug Application To FDA For Its Proprietary, Selective Cortisol Modulator, Relacorilant, To Treat Patients With Cushing's Syndrome
Corcept Therapeutics Submits New Drug Application To FDA For Its Proprietary, Selective Cortisol Modulator, Relacorilant, To Treat Patients With Cushing's Syndrome
Corcept醫療向FDA提交了新藥申請，以其專有的選擇性皮質醇調節劑Relacorilant治療庫欣綜合症患者。
Corcept Therapeutics Submits New Drug Application To FDA For Its Proprietary, Selective Cortisol Modulator, Relacorilant, To Treat Patients With Cushing's Syndrome
Corcept醫療向FDA提交了新藥申請，以其專有的選擇性皮質醇調節劑Relacorilant治療庫欣綜合症患者。
熱門討論
特朗普2.0時代倒計時！全球股市的下一個風口？
🎙️️討論： 1. 加密貨幣政策能否利好crypto? 2. 關稅政策能否利好中概等海外資產？
Popular on moomoo
01/13 17:43
特朗普2.0機會預告：在總統上任之前猜測市場贏家！